Oculis acquires full commercial rights to Privosegtor from Accure Therapeutics in USD 3.8 million deal

Oculis Holding has signed an asset purchase agreement with Accure Therapeutics to acquire full global development and commercial rights to Privosegtor and preclinical candidate ACT-02. The agreement involves $3.8 million in upfront cash and up to 2.05 million ordinary shares, replacing a prior licensing arrangement to maximize long-term commercial value.

Biopharmaceutical firm Oculis Holding has structured a definitive asset purchase agreement with Spain-based Accure Therapeutics to secure full global ownership of Privosegtor and an early-stage candidate. The deal, valued at $3.8 million in upfront cash alongside up to 2.05 million equity shares tied to lockup releases and clinical achievements, replaces a prior licensing framework. Upon formal closing, Oculis will absorb complete commercial and developmental control, eliminating previously established royalty commitments and performance milestones while directly assuming underlying institutional academic agreements.

Headquartered in Switzerland, Oculis Holding operates as a clinical-stage biopharmaceutical organization dedicated to developing novel therapeutic solutions for neuro-ophthalmic and ophthalmic disorders. Accure Therapeutics is a Barcelona-based translational neuroscience research entity focused on discovering disease-modifying treatments for central nervous system pathologies. Under the newly negotiated terms, transfer of the lead asset ACT-01 is scheduled to finalize by February 2027, followed by the secondary candidate ACT-02 by March 2027, pending standard regulatory and closing conditions.

Consolidating intellectual property rights under a unified corporate framework fundamentally restructures the asset's financial trajectory. By replacing variable royalty burdens with a fixed upfront payout and performance-contingent equity distributions, the acquirer optimizes prospective profit margins for downstream commercialization. Removing secondary licensors simplifies operational governance, allowing streamlined regulatory submissions, faster clinical trial execution, and unencumbered global distribution strategies. The transaction also offers early-stage neuroscience developers a model for monetizing clinical progress via equity participation while ensuring pipeline advancement.

This transaction signals broader consolidation trends across the biotechnology and pharmaceutical sectors, where late-stage clinical developers increasingly seek full asset control to eliminate financial friction prior to regulatory approval. In the specialized neuro-ophthalmology market, securing exclusive therapeutic rights reinforces competitive moats against emerging biological alternatives. Furthermore, the integration highlights growing cross-border collaboration between European translational research hubs and internationally listed biopharmaceutical platforms, reflecting sustained investor interest in targeted central nervous system and optic disease therapies.

From an investment perspective, transitioning from a licensing model to direct asset ownership shifts long-term valuation risk directly onto operational performance while offering enhanced strategic flexibility. Investors in biopharmaceutical ventures benefit from reduced capital leakage to third-party licensors during potential commercial rollouts. Additionally, structuring consideration through performance-based earnout shares aligns long-term financial incentives between originators and developers, preserving balance sheet liquidity while providing downside protection during pivotal clinical trials.